Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Study on Genetic Testing for Lung Cancer Patients After Surgery

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery.

Detailed description of study

The purpose of this study is to centrally test resected non-small cell lung cancer (NSCLC) for genetic mutations to facilitate accrual to randomized adjuvant studies, and to obtain clinically annotated tumor tissue and patient-matched non-malignant deoxyribonucleic acid (DNA) from peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to allow clinically annotated advanced genomic analyses in concert with the National Cancer Institute (NCI) Center for Cancer Genomics (CCG).

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: lung carcinoma,lung cancer,carcinoma,cancer,lung,lungs,oncology
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria

In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Clinical stage IB (>= 4 cm), II or IIIA non-squamous non-small cell lung cancer (NSCLC)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1

For a full list of participation criteria, please visit ClinicalTrials.gov.

Updated on 19 Feb 2024. Study ID: 1502674227 (A151216)

This study investigates genetic testing in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) that has been or will be removed by surgery. Non-small cell lung cancer is a type of lung cancer that grows and spreads more slowly than small cell lung cancer. The purpose of this study is to test the removed cancer tissue for genetic mutations. This helps in enrolling patients in further studies that look at additional treatments after surgery.

Participants will have their tumor tissue and blood samples collected. The study will include detailed follow-up to gather information about their health and treatment outcomes. This information will be used for advanced genetic analysis in collaboration with the National Cancer Institute.

  • Who can participate: Adults with stage IB (4 cm or larger), II, or IIIA non-squamous non-small cell lung cancer can participate. They must have a performance status of 0-1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
  • Study details: Participants will provide tumor tissue and blood samples for genetic testing. This testing identifies mutations that could guide further treatment. No medication or placebo is involved in this trial. A placebo is an inactive substance that looks like the investigational medicine/vaccine but does not contain any medicine.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here